Episode
Grifols (GRFS): Profit Jumped 29% — Until You Find the €109M Accounting Gain
- Published
- Jul 29, 2026
- Duration seconds
- 938
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/grifols-grfs-profit-jumped-29-until-you-find-the-109m-accounting-gain/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/grifols-grfs-profit-jumped-29-until-you-find-the-109m-accounting-gain.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Grifols, S.A. (GRFS) H1 2026 — Grifols, S.A. (NASDAQ: GRFS), the Barcelona-based plasma fractionator and one of only a handful of companies worldwide that can turn donated blood plasma into immunoglobulins, albumin and alpha-1 at scale, reported Half-Year 2026 results after the European close on July 28: revenue of €3,574M, +2.6% at constant currency but -2.8% as reported (a ~€197M FX translation drag), adjusted EBITDA of €854M at a 23.9% margin (+2.4% cc), and group profit of €227M, +28.7% YoY. Q2 standalone adjusted EBITDA of €472M at a 25.2% margin edged past ~€467M consensus. Free cash flow before M&A turned positive at +€91M versus -€12M a year earlier. But the headline profit jump is largely an accounting artifact: the April refinancing was treated under IFRS 9 as a debt modification rather than an extinguishment, producing a €109M NON-CASH gain in the finance result — more than the entire €50M increase in group profit. Strip it and H1 profit is nearer €145M, down ~18%. Net leverage was 4.2x on the credit-agreement basis — exactly where it stood a year ago — and 5.4x on full balance-sheet debt of €8,843M including leases. Adjusting for the €72M of LTM EBITDA consolidated from Haema and BPC Plasma (entities Grifols controls but whose equity its shareholders do not own) puts look-through leverage nearer 4.5x. Immunoglobulin grew +12.8% cc (subcutaneous/Xembify +17.7% H1, +33.9% in Q2), but albumin fell -14.2% cc (-20.8% in Q2) on a China price concession — and albumin is a joint product of the same litre of plasma. FY26 guidance was reaffirmed (adj. EBITDA margin ≥25%, +5-9% cc growth, FCF €500-575M), but H1 delivered 23.9% and +2.4%, so the second half must carry €409-484M of FCF, roughly 5x the H1 run rate. Critically, one GRFS ADR = one Class B NON-VOTING pr…